Evonik, a global specialty chemicals company, has named executive Elias Lacerda President of the Americas region, effective February 1, 2026.... Read more
Category: Uncategorized
Tech and Pharma Alliance Drives Patient-Centric Drug Development
The organization Citizen Health has entered into a multi-year strategic partnership with the pharmaceutical company UCB to expedite drug development... Read more
Historic Zero Tariff Pharmaceutical Deal Agreed Between US and UK
The US government and the United Kingdom have announced an agreement in principle regarding pharmaceutical trade, under which UK pharmaceutical... Read more
Breakthrough Gene Technology Collaboration for Rare Genetic Disorder
Regeneron and Tessera Therapeutics have entered into a global collaboration agreement to develop and commercialize TSRA-196, Tessera’s lead investigational in... Read more
US-UK Trade Deal: Drug Tariff Exemption Secured in Exchange for Healthcare Spending Reforms
The Trump administration and the United Kingdom have finalized a country-specific trade agreement that confers Washington’s largest pharmaceutical import tariff... Read more
Instability Signals and New Opportunities in the Rare Cardiovascular Market (ATTR-CM)
The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM)—once projected to become a $20 billion market—may have just revealed the first... Read more
Pharmaceutical Giants Pledge $370 Billion in US Investments Amid Onshoring Boom
According to a new fourth-quarter market trend report from DPR Construction, major drugmakers have collectively announced commitments exceeding $370 billion... Read more
Uncontrollable Vomiting Syndrome on the Rise: Warning Linked to Chronic Cannabis Use
A rare and unusual medical condition, known as Cannabis Hyperemesis Syndrome (CHS), is escalating in the United States. The disorder... Read more
Top FDA Drug Officer Set to Exit Weeks into New Role
The long-serving oncology chief of the U.S. Food and Drug Administration (FDA) has filed to retire from the agency, just... Read more









